Trxade Health Inc has a consensus price target of $1.42 based on the ratings of 3 analysts. The high is $1.75 issued by Maxim Group on March 28, 2023. The low is $1.25 issued by EF Hutton on June 1, 2023. The 3 most-recent analyst ratings were released by EF Hutton, EF Hutton, and Maxim Group on June 1, 2023, May 16, 2023, and March 28, 2023, respectively. With an average price target of $1.42 between EF Hutton, EF Hutton, and Maxim Group, there's an implied -81.34% downside for Trxade Health Inc from these most-recent analyst ratings.
1calculated from analyst ratings
The latest price target for Trxade Health (NASDAQ:MEDS) was reported by EF Hutton on June 1, 2023. The analyst firm set a price target for $1.25 expecting MEDS to fall to within 12 months (a possible -83.53% downside). 0 analyst firms have reported ratings in the last year.
The latest analyst rating for Trxade Health (NASDAQ:MEDS) was provided by EF Hutton, and Trxade Health their buy rating.
There is no last upgrade for Trxade Health
There is no last downgrade for Trxade Health.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Trxade Health, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Trxade Health was filed on June 1, 2023 so you should expect the next rating to be made available sometime around June 1, 2024.
While ratings are subjective and will change, the latest Trxade Health (MEDS) rating was a with a price target of $0.00 to $1.25. The current price Trxade Health (MEDS) is trading at is $7.59, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.